Midatech Pharma : Corporate Overview

Midatech Pharma plc

Corporate overview

June 2021

27/06/2021 1

Disclaimer

The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by Midatech Pharma PLC (the "Company").

The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities of the Company, nor shall it or any part of it, nor the fact of its distribution, form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto and the right is reserved to terminate any discussions or negotiations with any prospective investors.

The distribution of this Presentation may, in certain jurisdictions, be restricted by law. Persons in possession of this Presentation are required to inform themselves about and to observe any such restrictions. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of any documents or any amendment or supplement thereto (including but not limited to this Presentation) in any country or jurisdiction where specific action for that purpose is required. This Presentation does not constitute an offer or solicitation to purchase or subscribe for securities in the United States. The securities of the Company to which this Presentation relates have not been registered, and will not be registered, under the U.S. Securities Act of 1933, as amended, or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, any offer or sale of securities in the Company will only be offered or sold outside the United States in offshore transactions in accordance with Regulations S of the Securities Act. Neither the U.S. Securities and Exchange Commission ("SEC"), nor any other United States authority, has approved this Presentation. There will be no public offering of securities in the United States.

The Presentation is provided for general information only and does not purport to contain all the information relating to the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. In furnishing the Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update the Presentation or to correct any inaccuracies in, or omissions from the Presentation which may become apparent. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company.

By attending the meeting where this Presentation is made or by accepting a copy of this Presentation, you agree to be bound by these limitations and conditions and to maintain absolute confidentiality regarding the information disclosed in this Presentation. Without limiting the generality of the foregoing, the recipient acknowledges and agrees that (i) photocopying or other duplication or transmittal of the Presentation in whole or in part and the data provided for any purpose without prior written consent of the Company is strictly prohibited and (ii) the Company will not be subject to any liability based on the information contained in this Presentation, errors herein or omissions here from, whether or not the Company knows or should have known of any such errors of omissions, and / or was responsible for and /or participated in such error or omission from this Presentation.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future

27/06/2021 2

Midatech: Corporate overview

Drug delivery biotechnology company with disruptive proprietary micro and nano technology platforms

Rapid R&D innovation core to success, delivering First-in- Class sustained/ modified release therapeutics

Dual-listed on LSE AIM: MTPH and NASDAQ: MTP

Headquarters, R&D, pilot scale manufacturing in Cardiff,

UK

Approximately 20 employees

LEFT TO RIGHT: Fiona Sharp Group Controller, Sam Barker Director Business Development, Stephen Stamp CEO and CFO, Paul Seaman VP Pharmaceutical & Technology Development, Steve Damment EVP R&D

27/06/2021 3

Midatech: History and milestones

Establishment

• Company formed, acquired GNP technology from CSIC, Madrid

	Public Listing		Realignment
•	Listing on NASDAQ	•	MTD201 '102 trial reports
•	Acquired DARA Biosciences,	• Strategic Review, closure of Bilbao
	renamed MPUS	•	MTX110 Phase I data

2014	2018

2000	2015
IPO		Growth
• IPO on AIM market, London	•	Sale of MPUS
• Acquired Q-Chip,Q-Sphera technology	•	Focus on MTD201

2021

2020

Proving the model

• Delivered PoC (x2) to collaborator
• Q- brexpiprazole in vivo data
• Q- mAb encapsulation data

27/06/2021 4

Midatech: Patented drug delivery technologies

Improving the

bio-delivery

• • bio-distributionof medicines
• Optimized clinical solutions
• Improved health economics
• Reduced production cost
• Opportunities to extend life cycles of maturing drugs

Q-Sphera™	MidaSolve™	MidaCore™

	Sustained Delivery		Local Delivery	Targeted Delivery
•	Precision clinical	•	Converts oral meds into	• Ultra-small size (2-4nM)
	performance		liquid meds	• Can bind multiple agents:
		•
•	Advanced technology	Increases routes of	Targeting, Therapeutic
	administration
	manufacturing
	•
		Enables direct tumor
•	Distinct competitive		injection
	advantage

27/06/2021 5